Seqirus announced that the Food and Drug Administration (FDA) has approved the use of Afluria Quadrivalent (quadrivalent, inactivated “split virion” influenza vaccine) for use in patients aged ≥5 years for influenza immunization.
Afluria Quadrivalent was initially approved by the FDA for patients aged ≥18 years. Afluria Quadrivalent provides protection against two influenza A strain viruses and two influenza B strain viruses. The traditional seasonal influenza vaccine is a trivalent form that contains 2 strains of influenza A strain viruses and 1 strain of influenza B strain virus.
Data from a randomized, observer-blinded, comparator-controlled study (n=2,278) evaluating children aged 5–17 years showed that Afluria Quadrivalent vaccine was non-inferior to a comparator vaccine containing the same recommended virus strains.
BothAfluria and Afluria Quadrivalent are both available for the 2017/2018 flu season. They are available as prefilled syringes and as multi-dose vials. Afluria and Afluria Quadrivalent are also available with the PharmaJet Stratis device, a needle-free injection option for patients aged 18–64 years.
For more information call (855) 358-8966 or visit Afluria.com.